Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime

Molecular Neurobiology

Volumn 50, Issue 1, 2014, Pages 107-118

  Eckmann, Janett ^a   Clemens, Laura E ^b   Eckert, Schamim H ^a   Hagl, Stephanie ^a   Yu Taeger, Libo ^b   Bordet, Thierry ^c   Pruss, Rebecca M ^c   Muller, Walter E ^a   Leuner, Kristina ^a,d   Nguyen, Huu P ^b   Eckert, Gunter P ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Trophos   (France)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

BACHD rat; Huntington disease; Membrane cholesterol; Membrane fluidity; Mitochondrial membrane

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; CHOLESTEROL; OLESOXIME; CHOLEST 4 EN 3 ONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; DRUG EFFICACY; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; RAT; ANIMAL; BRAIN; CELL LINE; DISEASE MODEL; DRUG EFFECTS; HUNTINGTON DISEASE; MEMBRANE FLUIDITY; METABOLISM; MITOCHONDRION;

ANIMALS; BRAIN; CELL LINE; CHOLESTENONES; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MEMBRANE FLUIDITY; MICE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; RATS;

EID: 84911007903     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8663-3     Document Type: Article

References (94)

1. The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983
2. Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA (1993) Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2(10):1547–1549
3. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369–384
4. Nijtmans LGJ, Ugallde C, van den Heuvel LP, Smeitink JAM (2004) Function and dysfunction of the oxidative phospharylation system. In: Koehler C, Bauer MF (eds) Mitochondrial function and biogenetics. Springer Inc., Heidelberg, pp 149–167
5. Wisniewska A, Draus J, Subczynski WK (2003) Is a fluid-mosaic model of biological membranes fully relevant? Studies on lipid organization in model and biological membranes. Cell Mol Biol Lett 8(1):147–159
6. Helmreich EJ (2003) Environmental influences on signal transduction through membranes: a retrospective mini-review. Biophys Chem 100(1–3):519–534
7. Los DA, Murata N (2004) Membrane fluidity and its roles in the perception of environmental signals. Biochim Biophys Acta 1666(1–2):142–157
8. Maxfield FR, Tabas I (2005) Role of cholesterol and lipid organization in disease. Nature 438(7068):612–621
9. Peters I, Igbavboa U, Schutt T, Haidari S, Hartig U, Rosello X, Bottner S, Copanaki E, Deller T, Kogel D, Wood WG, Muller WE, Eckert GP (2009) The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta 1788(5):964–972
10. Fajardo VA, McMeekin L, LeBlanc PJ (2011) Influence of phospholipid species on membrane fluidity: a meta-analysis for a novel phospholipid fluidity index. J Membr Biol 244(2):97–103
11. Comte J, Maisterrena B, Gautheron DC (1976) Lipid composition and protein profiles of outer and inner membranes from pig heart mitochondria. Comparison with microsomes. Biochim Biophys Acta 419(2):271–284
12. Montecucco C, Smith GA, Dabbeni-sala F, Johannsson A, Galante YM, Bisson R (1982) Bilayer thickness and enzymatic activity in the mitochondrial cytochrome c oxidase and ATPase complex. FEBS Lett 144(1):145–148
13. Madden TD, Hope MJ, Cullis PR (1983) Lipid requirements for coupled cytochrome oxidase vesicles. Biochemistry 22(8):1970–1974
14. Ricchelli F, Gobbo S, Moreno G, Salet C (1999) Changes of the fluidity of mitochondrial membranes induced by the permeability transition. Biochemistry 38(29):9295–9300
15. Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP, Letellier T, Dachary-Prigent J, Solaini GC, Rossignol R (2005) Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 37(4):207–225
16. Colell A (2003) Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. J Biol Chem 278(36):33928–33935
17. Garofalo T, Tinari A, Matarrese P, Giammarioli AM, Manganelli V, Ciarlo L, Misasi R, Sorice M, Malorni W (2007) Do mitochondria act as “cargo boats” in the journey of GD3 to the nucleus during apoptosis? FEBS Lett 581(21):3899–3903
18. Gouarné C, Tardif G, Tracz J, Latyszenok V, Michaud M, Clemens LE, Yu-Taeger L, Nguyen HP, Bordet T, Pruss RM (2013) Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease. PLoS One 8(11):e81528
19. Jin YN, Yu YV, Gundemir S, Jo C, Cui M, Tieu K, Johnson GV (2013) Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One 8(3):e57932
20. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795
21. Browne SE (2008) Mitochondria and Huntington’s disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 1147:358–382
22. Reddy PH, Mao P, Manczak M (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev 61(1):33–48
23. Oliveira JM (2010) Mitochondrial bioenergetics and dynamics in Huntington’s disease: tripartite synapses and selective striatal degeneration. J Bioenerg Biomembr 42(3):227–234
24. Rosenstock TR, Duarte AI, Rego AC (2010) Mitochondrial-associated metabolic changes and neurodegeneration in Huntington’s disease—from clinical features to the bench. Curr Drug Targets 11(10):1218–1236
25. Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13(14):1407–1420
26. 2+in transgenic Huntington disease rats. J Biol Chem 283(45):30715–30724
27. Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28(11):2783–2792
28. Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18(4):737–752
29. Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, Malorni W, Davies KJ, Carafoli E, Scorrano L (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol Med 2(12):490–503
30. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet 19(20):3919–3935
31. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet 20(7):1438–1455
32. Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, Perkins G, Bossy-Wetzel E (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 17(3):377–382
33. Trushina E, Dyer RB, Badger JD 2nd, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, Parisi JE, Seeberg E, Dragatsis I, Doyle K, Bender A, Chacko C, McMurray CT (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24(18):8195–8209
34. Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731–736
35. Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280(35):30773–30782
36. Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, Fariello RG (1990) l-Acetyl-carnitine in Huntington’s disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 5(3):263–265
37. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 22(5):1592–1599
38. Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of l-carnitine in a transgenic animal model of Huntington’s disease. Biomed Pharmacother 64(4):282–286
39. Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF (2012) Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington’s disease. Mol Cell Neurosci 49(2):149–157
40. Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet 21(5):1124–1137
41. Sandhir R, Sood A, Mehrotra A, Kamboj SS (2012) N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington’s disease. Neurodegener Dis 9(3):145–157
42. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, Lacapere JJ, Massaad C, Schumacher M, Steidl EM, Maux D, Delaage M, Henderson CE, Pruss RM (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322(2):709–720
43. Gincel D, Zaid H, Shoshan-Barmatz V (2001) Calcium binding and translocation by the voltage-dependent anion channel: a possible regulatory mechanism in mitochondrial function. Biochem J 358(Pt 1):147–155
44. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N (2010) VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 31(3):227–285
45. Hu J, Zhang Z, Shen WJ, Azhar S (2010) Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 7:47
46. Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, Gouarné C, Raoul C, Pruss RM, Bordet T, Pettmann B (2012) Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 62(7):2346–2352
47. Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM (2009) Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 147(1–3):202–209
48. Xiao WH, Zheng H, Bennett GJ (2012) Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 203:194–206
49. Bordet T, Berna P, Abitbol JL, Pruss R (2010) Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel) 3:345–368
50. Eckmann J, Eckert SH, Leuner K, Muller WE, Eckert GP (2013) Mitochondria: mitochondrial membranes in brain ageing and neurodegeneration. Int J Biochem Cell Biol 45:76–80
51. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP (2012) A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J Neurosci 32(44):15426–15438
52. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182–6195
53. Eckert GP, Wood WG, Muller WE (2001) Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm 108(8–9):1051–1064
54. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
55. Kirsch C, Eckert GP, Muller WE (2003) Statins affect cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65(5):843–856
56. Kirsch C, Eckert GP, Mueller WE (2002) Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides. Amyloid 9(3):149–159
57. Choe M, Jackson C, Yu BP (1995) Lipid peroxidation contributes to age-related membrane rigidity. Free Radic Biol Med 18(6):977–984
58. Lentz BR (1988) Membrane fluidity from anisotropy measurements. In: Loew LM (ed) Spectroscopic membrane probes, vol 1. CRC, Boca Raton, pp 13–42
59. Tellez-Nagel I, Johnson AB, Terry RD (1974) Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol 33(2):308–332
60. Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28(1):23–31
61. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12(5):497–508
62. Petrasch-Parwez E, Nguyen HP, Lobbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O, Andres KH, Dermietzel R, Von Horsten S (2007) Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 501(5):716–730
63. Turner C, Schapira AH (2010) Mitochondrial matters of the brain: the role in Huntington’s disease. J Bioenerg Biomembr 42(3):193–198
64. Ciarlo L, Manganelli V, Matarrese P, Garofalo T, Tinari A, Gambardella L, Marconi M, Grasso M, Misasi R, Sorice M, Malorni W (2012) Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington’s disease. J Lipid Res 53(10):2057–2068
65. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16(1):61–77
66. LaFontaine MA, Geddes JW, Butterfield DA (2002) 3-nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington’s disease 1. Neurochem Res 27(6):507–511
67. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington’s disease phenotype in experimental animals. Prog Neurobiol 59(5):427–468
68. Schroeder F, Goetz IE, Roberts E (1984) Membrane anomalies in Huntington’s disease fibroblasts. J Neurochem 43(2):526–539
69. Eckert GP, Igbavboa U, Muller WE, Wood WG (2003) Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains. Brain Res 962(1–2):144–150
70. Eckert GP, Muller WE (2009) Presenilin 1 modifies lipid raft composition of neuronal membranes. Biochem Biophys Res Commun 382(4):673–677
71. Wood WG, Igbavboa U, Muller WE, Eckert GP (2011) Cholesterol asymmetry in synaptic plasma membranes. J Neurosci 116(5):684–689
72. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 4(1):17–23
73. Karasinska JM, Hayden MR (2011) Cholesterol metabolism in Huntington disease. Nat Rev Neurol 7(10):561–572
74. Valenza M, Cattaneo E (2011) Emerging roles for cholesterol in Huntington’s disease. Trends Neurosci 34(9):474–486
75. Leoni V, Caccia C (2013) 24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie 95(3):595–612
76. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E (2010) Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J Neurosci 30(32):10844–10850
77. Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De Mario A, Zuccato C, Di Donato S, Carafoli E, Cattaneo E (2012) Pitfalls in the detection of cholesterol in Huntington’s disease models. PLoS Curr 4:e505886e9a1968
78. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 92(15):7105–7109
79. Damiano M, Galvan L, Deglon N, Brouillet E (2010) Mitochondria in Huntington’s disease. Biochim Biophys Acta 1802(1):52–61
80. Burchell VS, Gandhi S, Deas E, Wood NW, Abramov AY, Plun-Favreau H (2010) Targeting mitochondrial dysfunction in neurodegenerative disease: part II. Expert Opin Ther Targets 14(5):497–511
81. Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB, Perry G, Smith MA (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802(1):212–220
82. Shoshan-Barmatz V, Ben-Hail D (2012) VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion 12(1):24–34
83. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9(12):971–988
84. Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G (2007) Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands. Neuropharmacology 53(2):318–329
85. Miccoli L, Oudard S, Beurdeley-Thomas A, Dutrillaux B, Poupon MF (1999) Effect of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide (PK11195), a specific ligand of the peripheral benzodiazepine receptor, on the lipid fluidity of mitochondria in human glioma cells. Biochem Pharmacol 58(4):715–721
86. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM (2003) Chenodeoxycholate induction of mitochondrial permeability transition pore is associated with increased membrane fluidity and cytochrome c release: protective role of carvedilol. Mitochondrion 2(4):305–311
87. Mattson MP, Liu D (2003) Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem Biophys Res Commun 304(3):539–549
88. Jana NR, Zemskov EA, Wang G, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10(10):1049–1059
89. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E (2008) Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 283(9):5780–5789
90. Wang X, Zhu S, Pei Z, Drozda M, Stavrovskaya IG, Del Signore SJ, Cormier K, Shimony EM, Wang H, Ferrante RJ, Kristal BS, Friedlander RM (2008) Inhibitors of cytochrome c release with therapeutic potential for Huntington’s disease. J Neurosci 28(38):9473–9485
91. Magalon K, Zimmer C, Cayre M, Khaldi J, Bourbon C, Robles I, Tardif G, Viola A, Pruss RM, Bordet T, Durbec P (2012) Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol 71(2):213–226
92. Rivard AL, Steer CJ, Kren BT, Rodrigues CM, Castro RE, Bianco RW, Low WC (2007) Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am J Chin Med 35(2):279–295
93. Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, Steer CJ (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75(6):2368–2379
94. Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol 171(2):351–360